GlassScriptPhysician profile
Luqman K Dad
NPI 1013136886
$7,769.04
in general payments reported to CMS, 2019-2025
34 companies · $136 in 2025
The $136 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,766 · 2020: $744 · 2021: $2,387 · 2022: $477 · 2023: $538 · 2024: $722 · 2025: $136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $703 · Food and Beverage: $693.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $702.65 |
| Food and Beverage | $693.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,633.90 | 2020-2021 | |
| Astrazeneca Uk Limited | $1,404.06 | 2019 | |
| Brainlab, INC. | $1,362.16 | 2019 | |
| Elekta, INC. | $702.65 | 2024 | |
| Siemens Medical Solutions USA, INC. | $369.49 | 2023 | Varian Ethos Treatment Planning |
| Tactile Systems Technology INC | $195.76 | 2021-2025 | Nimbl, Flexitouch Plus |
| Genzyme Corporation | $115.46 | 2021-2022 | |
| Gt Medical Technologies, INC | $113.56 | 2023 | Gammatile |
| Regeneron Healthcare Solutions, INC. | $94.39 | 2021-2022 | |
| Boston Scientific Corporation | $74.74 | 2021-2024 | Rezum Generator |
| Eisai INC. | $66.79 | 2021-2022 | |
| Lilly USA, LLC | $47.78 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $45.03 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.78 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $43.37 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmaessentia USA Corporation | $41.86 | 2022 | |
| Tersera Therapeutics LLC | $36.71 | 2023 | Xermelo |
| Bayer Healthcare Pharmaceuticals INC. | $33.62 | 2021 | |
| Novartis Pharmaceuticals Corporation | $32.11 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $28.27 | 2022 | |
| Seagen INC. | $27.70 | 2021 | |
| Janssen Biotech, INC. | $26.47 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.55 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $24.71 | 2022 | |
| Pharmacosmos Therapeutics INC. | $23.93 | 2021 | |
| Global Blood Therapeutics, INC. | $23.15 | 2022 | |
| Servier Pharmaceuticals LLC | $21.61 | 2022 | |
| Coherus Oncology, INC. | $19.58 | 2021 | |
| Amgen INC. | $18.58 | 2021 | |
| Adaptive Biotechnologies Corporation | $15.01 | 2022 | |
| Incyte Corporation | $14.99 | 2021 | |
| Celgene Corporation | $14.84 | 2021 | |
| Array Biopharma INC | $14.73 | 2021 | |
| Alnylam Pharmaceuticals INC. | $11.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luqman Dad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.